Company
Ergomed PLC
LON:ERGO
Ergomed PLC provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. The company's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO).
204 stories · page 1 of 3
Has British biotech outgrown the Square Mile?
The UK capital markets fail to price British biotech innovators fairly
Small cap movers: Ergomed and Instem highlight grim trend
Private equity firms ar targeting undervalued UK life sciences companies
Ergomed seeing sold growth in 2023
The AIM-quoted firm is studying two antibodies in COVID-19 cases
Ergomed sees 'solid' revenue growth so far this year
Financial results for the full year 2023 are in line with market expectations
Ergomed a 'premium quality' business, suggests broker
Earnings growth should average 12% annually over the next three years
Ergomed well positioned in high growth niches, says broker
Orders grew to £284.5m (up 25% yoy), which provides strong visibility on revenues
Archive
Small Cap Feast - Ergomed and more...
27 September 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**Streaks Gaming plc, a UK-bas
Ergomed confident for rest of 2022 and beyond
Orders during the half rose to £285mln, up nearly 19% from the start of the year.
Ergomed revenues rise 25% as pharma services demand stays healthy
In February, it acquired ADAMAS, a quality assurance specialist
Ergomed appoints former GSK and Sanofi executive to board
Anne Whitaker has worked across the pharmaceutical, biotech and speciality pharma sectors for 30 years
Ergomed earnings exceed expectations; says order book worth £240mln
The pharma services specialist gave an upbeat assessment of prospects
Ergomed strengthens pharma quality arm with £25mln acquisition
ADAMAS is focused on areas such as Good Clinical Practice (GCP) and Good Pharmacovigilance Practice (GVP)
Ergomed targets expansion into Asia with necessary ‘firepower’ for M&As
The company said its EBITDA will be ahead of current market expectations in its report today
Ergomed shares jump 9% after better-than-expected trading update; broker bullish
Peel Hunt, the company’s joint broker, said it has been impressed by the 2021 numbers, “especially given the foreign exchange headwinds for the majority of the year”
Ergomed says its earnings will beat market expectations; co "extremely confident" about the future
The growth of the US business the stand-out feature of the company’s performance
Ergomed confident on outlook after strong interim results
Total revenue climbed 39% to £56mln, with adjusted underlying earnings (EBITDA) up 33% to £12mln
Ergomed sees exceptional first half performance
"Ergomed has delivered exceptional results and operational progress during the first half of the year,” said executive chair Dr Miroslav Reljanović.
Ergomed senior independent director to step down
The company said Rolf Soderstrom has decided to step down to focus on other business activities but will remain on the board until September 30 to provide a period of transition
Ergomed sees earnings ahead of expectations as chairman highlights strong start to 2021
Dr Miroslav Reljanović says the pharma services firm has built on the momentum of 2020 and made a strong start to the current year.
Ergomed appoints Shire's former head of corporate development as a non-exec
Mark Enyedy is currently chief executive of Nasdaq-listed ImmunoGen
Ergomed opens PrimeVigilance business in Japan
The Japanese pharmaceutical market is the fourth-largest in the world after the US, the EU and China
Ergomed in strong position after storming performance in 2020
In 2020 there was a strong operational and financial performance from both of the group's businesses, Pharmacovigilance (PV) and Clinical Research Services (CRO), the company said.
Ergomed says 2020 adjusted underlying earnings will be ahead of market expectations
The company said the outlook for 2021 is positive, bolstered by the strong order book and the acquisitions of Ashfield PV and MedSource.
Ergomed gains as it expands its US footprint in earnings enhancing deal worth up to US$25mln
Chairman, Dr Miroslav Reljanović, said the addition of MedSource builds on the successful acquisition and integration of Ashfield Pharmacovigilance, now PrimeVigilance USA, earlier this year
Ergomed confident of continued momentum after exceptional first half
"Ergomed has delivered exceptional progress both operationally and financially during the first half of the year,” said Miroslav Reljanović, the group's executive chairman
Ergomed says full-year earnings to be “materially ahead of market expectations”
The group, which provides services to the pharma industry such as contract research and drug monitoring, gave the update after assessing its first-half performance
Archive
Proactive news headlines: e-therapeutics, Ergomed, Metal Tiger, Tower Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Ergomed executive chairman says firm “had a good first quarter, with solid overall growth in revenue”
Dr Miroslav Reljanović added: “At this time the Company is confident that results will be in line with current market expectations for the 2020 financial year”
Ergomed’s PrimeVigilance inks collaboration deal to accelerate intelligent automation strategy
The partnership with Automation Anywhere and DataRobot is expected to deliver organic growth more efficiently with the automation of manual, repetitive processes
Archive
Ergomed to help run second trial in Italy targeting possible coronavirus treatments
The programme is being conducted at the Humanitas Research Hospitals in Bergamo and Milan
Ergomed highlights first data from coronavirus study at Bergamo in Italy
Ergomed is providing clinical development and research services including significant involvement in the study's design and implementation
Ergomed's PrimeVigilance supports coronavirus trial
The company is providing the services through its specialist pharmacovigilance provider as part of an ongoing clinical trial
Ergomed seeing high levels of interest for coronavirus research services
The AIM-quoted pharma-services firm is supporting clinical coronavirus research in Bergamo, Italy
Ergomed reveals it is providing clinical research services for a study in Italy for the treatment of patients with coronavirus
The group noted that the study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA)
Ergomed's underlying earnings set to top expectations after a strong year
The firm, which provides support services to the drug industry, said its “focus on profitability” meant adjusted EBITDA would be ahead of current market forecasts
Ergomed jumps following acquisition drug safety firm of Ashfield Pharmacovigilance
The acquisition will add over 40 new clients to Ergomed's roster as well as contracted revenues worth around US$9.8mln
Ergomed hails a strong first-half as order book continues to grow
The company also said it was on track to hit full-year forecasts
Archive
First big wave of corporate results to hit on Thursday: BT, Unilever, Shell, Diageo to stand out
Aside from the tide of blue-chip results, some big second line news will also flow on Thursday from the likes of Britvic, Dairy Crest, Premier Oil, Rank Group, and Renishaw
Archive
Quality and quantity on the company news front, but Brexit vote, Fed rates, US jobs to be key
The cream of the corporate updates will likely come from blue-chips BT Group, Royal Mail, Royal Dutch Shell, Unilever and Diageo
Archive
Proactive news snapshot: Pan African Resources, Strategic Minerals, Strategic Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Mission Marketing Group shares step up, United Carpets declines
A look at some of the biggest risers and fallers in the UK market on Wednesday
Hardware & electrical equipment
Ergomed's cost-cutting programme to yield £4mln in savings each year
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Investments and investor services
FTSE 100 closes higher as trade fears ebb; Kingfisher leads the laggards
The FTSE 100 closed nearly 31 points higher at 7,331, while FTSE 250 added over 42 at 20,500
Archive
Kingfisher feeling blue across La Manche
DIY retailer Kingfisher has seen a decent performance by B&Q and Screwfix blighted by seemingly irreparable problems at its Castorama chain in France
Archive
UK inflation and retail sales data eyed, plus trading updates from Kingfisher and Ocado
Aside from the UK data and the retail updates, the Week Ahead will also bring news from the likes of Diageo, Dairy Crest, Smiths Group, Lamprell, and SIG
Ergomed revenue delay leads to Numis downgrade
The AIM-listed pharmaceuticals developer said the contract delays meant that its first-half revenue was expected to be “below management’s expectations”
Archive
Proactive news snapshot: Midatech Pharma. Westminster Group, Echo Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Defenx chief executive to leave after just six months
Some of the main news-driven risers and fallers in London on Friday afternoon...
Ergomed brings in new hire to bolster PrimeVigilance service offering
The AIM-listed company said it had appointed Dr Michael Forstner as head of risk management and pharmacoepidemiology
Archive
FTSE 100 closes higher but gives up gains; sterling hit on Brexit worries
Both the US and UK are heading towards a three-day weekend and, to be honest, it kind of feels like the break has already begun...
Archive
Proactive news snapshot: Flying Brand, Ergomed, Landore Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Zinc Media on the front foot after CEO and finance chief buy shares
A look at some of the top risers and fallers in London today
Ergomed sees strong rise in backlog of contracted revenue
2017 saw a continued strong performance for Ergomed in the services business and particularly in the Drug Safety and Medical Information business, said company chairman, Peter George
Investments and investor services
FTSE 100 closes in red amid trader tensions but Tesco soars
FTSE 100 closed in the red - down around nine points at 7,257
Archive
Tesco's results to be a "positive catalyst" for the share price
Updates are expected from Tesco, ASOS, PageGroup and McCarthy & Stone
Archive
Retailers and recruiters in focus as Tesco, ASOS, Hays and PageGroup report
The week ahead includes full-year results from Tesco and Saga, interims from ASOS, WH Smith and McCarthy & Stone, and trading updates from Robert Walters, Hays and PageGroup
Archive
Utilities dominate week ahead with updates from Pennon, United Utilities and SSE
The week ahead includes trading updates from Pennon, United Utilities and SSE, along with interims from DFS Furniture and full year results from Moss Bros and AG Barr
Archive
Proactive news snapshot: Union Jack Oil, appScatter Group, Ergomed …
A glance at some of the day's highlights from the Proactive Investors newswire
Interserve boosted by report Scottish multi-millionaire spearheading a rescue bid
A look at some of the biggest risers and fallers in London on Monday
Ergomed's year of exceptional growth and clinical success overshadowed by foreign exchange adjustments
Last-minute adjustments to 2017's earnings and R&D expenses have somewhat taken the shine off what was an excellent year for Ergomed
Archive
FTSE 100 closes higher as US benchmarks stage turnaround
FTSE 100 closed around 46 points higher at 7,115. Little brother FTSE 250 also gained ground - up over 180 points at 19,567.
Archive
Proactive news snapshot: Stratex International, Diversified Gas & Oil, Keywords Studios …
A glance at some of the day's highlights from the Proactive Investors newswire
Spectra Systems counting the coins as it says 2017 will be ahead of expectations
Some of the main news-driven risers and fallers on Thursday...
Ergomed raises £3.9mln as it looks to develop its PrimeVigilance business
The AIM company issued 2.03mln new shares – equivalent to around 5% of the company – at 190p apiece
Investments and investor services
FTSE 100 closes in red but broadcaster ITV shines
Footsie finished down over 43 points at 7,490, while FTSE 250 was also lower - down around 58 points at 20,185.
Archive
Proactive news snapshot: Summit Therapeutics , Minds + Machines, Itaconix, Accesso Technology …
A glance at some of the day's highlights from the Proactive Investors newswire
Ergomed update underlines the potential of the company's PrimeVigilance unit
According to one City number cruncher, Ergomed’s drugs safety unit alone is worth as much as the whole business
Investments and investor services
Smith & Nephew tops the Footsie after upgrade from JP Morgan Cazenove
Further down the food chain, Avacta, the company behind the Affirma technology - small, engineered proteins that are capable of binding specific molecular targets - got a lift from a research report by Capital Network.
Ergomed ready to kick on after a strong year
The pharma services and drug development company posted total sales of £47mln for the period to December 31, up 21%, while net service revenues were ahead 35% at £39mln
Investments and investor services
FTSE 100 closes lower as Euro gains ground
Britain's blue-chip benchmark finished around 27 points lower at 7,615.
Archive
Proactive news snapshot: Ortac Resources, Ceres Power Holdings, Bacanora Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Ceres Power Holdings surges as market cheers update
We take a look at some of the major movers - risers and fallers - in London on Friday.
Ergomed's finance chief appointed chief executive; welcomes new COO
Stamp has held senior roles at a number of healthcare businesses in the UK and US, the firm said
FTSE 100 ends at high point of the day but just short of 7,500
A slump in the value of the pound was, as usual, a signal for investors to pile into FTSE 100 stocks
Archive
Proactive news snapshot: ValiRx, W Resources, Falcon Oil & Gas …
A glance at some of the day's highlights from the Proactive Investors newswire
Surprise trading update is just the job for Robert Walters
The trading update was short and sweet. Liberum responded by increasing its target price.
Allergy Therapeutics teams up with Ergomed to take its anti-allergy tablets through the clinic
Allergy already has injectable vaccines for dust mites and tree and grass pollen, but it has brought in Ergomed to take the tablet formulations through clinical trials
FTSE 100 closes higher as energy stocks provide a boost; supermarkets weigh
Robert Walters sprang a pleasant surprise on the market with an unscheduled trading update.
Archive
Proactive news snapshot: Alliance Pharma, TyraTech, Galileo Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Elegant Hotels rejects bid approach from Melia Hotels
By the time it has confirmed press speculation, the bid approach was a dead duck
Ergomed to present at the International Society of Pharmacovigilance's Intelligent Automation
Can automated processes powered by artificial intelligence provide effective solutions to the ever-increasing challenges in pharmacovigilance?
FTSE 100 closes higher; miners lag and Brexit wranglings continue
FTSE 100 closed over 38 points higher on the day to 7,338; FTSE 250 shares added over 81
Archive
Proactive news snapshot: Premier African Minerals, Ergomed, ANGLE …
A glance at some of the day's highlights from the Proactive Investors newswire
Ergomed hopes to have PeproStat on the market by 2020 as it sails through Phase II trials
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”
Ergomed PSR acquisition seen as a “good fit”
Numis rates Ergomed a 'buy' with a 280p target price